Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Nov 19, 2024 6:09pm
260 Views
Post# 36320648

My thanks , philosophical thoughts

My thanks , philosophical thoughts

My thanks to notable. In a tough environment of FUDsters, you keep updating important information.
keeping in mind the best & most accurate & reliable source of information is the oncolytics biotec web site.
Certainly worth a read.
The " corporate update, PDF", is a clean & clear representation of progress & expectations.
On this site we seem to have a never ending stream of chatter, from a limited few.
All of what the6y post, is intentional twisting of various statements or details. Creating a negative vibe.
some of whom have identified they don't even own shares.

motivation?

Why would anyone devote time & energy to post thoughts, to discredit a company on its community chat site. aKA this one?
Granted it would be off balance as a minium to bash one's own investment.
The motivation, therfore must be to influence & hope to drive the price down.
Either to buy @ a lower level, or further profit from short positions.
Regardless, Sadly we have to read the drivel spouted.
Broader picture. The options have not changed.
buy, hold or sell ?

Sitting reading, right now...what matters is can Onc get Pela to market?
if they do, then & only then will the proper valuation come to light.

There is a process in place & history of trial results that indicate Onc will get Pela approved. Most likeky for MBc and pancreatic cancers.
Additionally, they have broader sucsess within the Goblet trial. CAR-t , and ongoing triple neg breast cancer with Incyte.
Regardless of when, they need a $$ partner to proceed with the MBc route.
The pancreatic cancer trial will be defined soon. That being a co- therapy with Roche.
again, regardless of time. The most recent trial results were viewed as positive, hence the announcement, october. Discussing the upcoming trials. Not to forget the $5million grant from PanCan to fund an additional arm....aka perhaps yet another marketing opportunity.
Buy, sell or hold?

I did buy some more a few weeks ago. Being around & holding a long time, lowers my break- even & increases my uoside.
Sell? ...profit taking. Not impossible. Protecting loss opportunities? A decision based on fear or not understanding the opportunities.
Hold.?  

That is essentially my opinion right now, today.
I believe the science is strong. I know they MUST get a business deal & soon, to move forward.
The latest corporate update indicates potential of $2.5 billion in sales/year , just for the MBc cancer.
That number puts Onc into a much higher position than we see now.
That is essentially where the analysts get their 12 month target of , as we hear now, $5/ps mid range.
That target does not include a buyout price.
Analysts don't do buyout projections unless there is public talk of a takeover.
Like it or nit, they do have to provide data , to back their projections.
Few appreciate: Onc negotiated a deal with PanCan to proceed with the pancreatic cancer trial.
Sadly PanCan lost their funding & cancelled ALL future trials.
That put Onc in a huge logistical horror.
Those who go on & on  bashing manegement, fail to give credit.
They were able to turn thst disaster around & team up with CGAR.
Yes, causing delays. The CGAR oppotunity, includes the $5 million grant, for the additional new Gobblet arm.
So, insult away. I don't care.
My Onc holdings are in until something happens.
if I thought, the science was wrong, I would have sold long ago.
My best guess, they will be bought out & soon.
The most recent news & conference call was very positive.
A few business observations. The ATM use has been minimal. Volume in general minimal.
Yes the long history is hurting the price. So is the increased shorting.
if I had zero shares right now, I'd be buying.
The upside opportunity & evidence far outweigh the downside risk.
A potential multi use cancer drug, in co- therapy with Roche......worth much more than where we are now.
 


 

<< Previous
Bullboard Posts
Next >>